Biobetters Trends: Market Research Report

December 2013 | 14 pages | ID: B8F2E1B4BC9EN
Global Industry Analysts, Inc

Abstracts

The report analyzes and presents an overview of Biobetters market worldwide. 'Biobetters or Biosuperiors are novel molecules derived from successful, approved biologic products that have been customized to enhance its overall efficacy. The primary characteristics targeted by these applicants include extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. These molecules contain the same active ingredients such as antibodies to target the same protein, but feature different chemical or molecular properties than the original drug.'

The report further discusses about applications, future prospects, and comparison of biobetters with originator drugs and biosimilars along with the strategic industry activities of major companies worldwide. In addition, major companies operating in the Biobetters arena worldwide including Amgen Inc., Cantab Biopharmaceuticals Ltd., Crucell NV, GreenCross Corporation, Hanmi Pharm Co. Ltd., Medgenics Inc., PharmaEssentia Corporation, Polytherics Ltd., SynBio LLC, Teva Pharmaceutical Industries Ltd., Xencor Inc., and others are profiled.

Contents

1. BIOBETTERS – A BIG TICKET OPPORTUNITY

A Prelude
Biobetters – A Better Bet
Originator Drugs vs. Biobetters
Biosimilars vs. Biobetters

2. MARKET TRENDS

An Evolution from Biotherapeutics to Biologics
Biobetter - The Gold Rush
Biotechnology Start-ups Focus on Biobetter Route
US Regulatory Scenario

3. RECENT INDUSTRY ACTIVITY

Synthon Takes Over Key Platforms of Biolex Therapeutics
Xencor Signs Agreement with Boehringer Ingelheim
Catalent Pharma Solutions Inks Agreement with Aptuit
Compass Biotechnologies Establishes New Subsidiaries
Human Stem Cells Institute Announces SynBio Project
Lancaster Laboratories Enters into Partnership with BioAzure Technologies
Momenta Pharmaceuticals Inks Agreement with Virdante Pharmaceuticals
PolyTherics Inks Agreement with DSM BioSolutions
Watson Pharmaceuticals Acquires Eden Biopharm Group

4. MARKET PARTICIPANTS

Amgen, Inc. (USA)
Bolder BioTechnology, Inc. (USA)
Boryung Pharmaceutical Co. , Ltd. (Korea)
Caliber Biotherapeutics LLC (USA)
Cantab Biopharmaceuticals Ltd. (UK)
Celtrion, Inc. (Korea)
ChromaCon AG (Switzerland)
Crucell NV (The Netherlands)
F. Hoffmann-La Roche Ltd. (Switzerland)
Flamel Technologies SA (France)
Genentech, Inc. (USA)
Glycotope GmbH (Germany)
GreenCross Corporation (Korea)
HanAll BioPharma Co. , Ltd. (Korea)
Hanmi Pharm Co. , Ltd. (Korea)
Harvest Moon Pharmaceuticals USA, Inc. (USA)
Medgenics, Inc. (USA)
OPKO Health Inc. (USA)
Pfizer, Inc. (USA)
PharmaEssentia Corporation (Taiwan)
Pieris AG (Germany)
Polytherics Ltd. (UK)
rEVO Biologics (USA)
Sutro Biopharma, Inc. (USA)
SynBio LLC (Russia)
Synthon (The Netherlands)
Teva Pharmaceutical Industries Ltd. (Israel)
Theramyt Novobiologics Pvt. , Ltd. (India)
Vitapharm Technology Development Co. , Ltd. (China)
Xencor, Inc. (USA)

5. APPENDIX